Filing Details

Accession Number:
0001104659-19-041306
Form Type:
4
Zero Holdings:
No
Publication Time:
2019-07-22 16:31:32
Reporting Period:
2019-07-22
Accepted Time:
2019-07-22 16:31:32
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1680581 Fulcrum Therapeutics Inc. FULC () DE
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1534260 Casdin Partners Gp, Llc 1350 Avenue Of The Americas
Suite 2600
New York NY 10019
No No Yes No
1534261 Casdin Capital, Llc 1350 Avenue Of The Americas
Suite 2600
New York NY 10019
No No Yes No
1534264 Eli Casdin 1350 Avenue Of The Americas
Suite 2600
New York NY 10019
No No Yes No
1534265 Casdin Partners Master Fund, L.p. 1350 Avenue Of The Americas
Suite 2600
New York NY 10019
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2019-07-22 464,285 $0.00 464,285 No 4 C Indirect See footnote
Common Stock Acquisiton 2019-07-22 125,000 $16.00 589,285 No 4 P Indirect See footnote
Common Stock Acquisiton 2019-07-22 10,000 $14.50 599,285 No 4 P Indirect See footnote
Common Stock Acquisiton 2019-07-22 5,000 $14.50 604,285 No 4 P Indirect See footnote
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 C Indirect See footnote
No 4 P Indirect See footnote
No 4 P Indirect See footnote
No 4 P Indirect See footnote
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Series B Preferred Stock Disposition 2019-07-22 3,250,000 $0.00 464,285 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 No 4 C Indirect
Footnotes
  1. On July 22, 2019, the Series B Preferred Stock converted into Common Stock on a seven-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.
  2. The securities are owned directly by Casdin Partners Master Fund, LP and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to Casdin Partners Master Fund, LP, (ii) Casdin Partners GP, LLC, the general partner of Casdin Partners Master Fund LP, and (ii) Eli Casdin, the managing member of Casdin Capital, LLC and Casdin Partners GP, LLC.